Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:2870 |
Name | endometrial adenocarcinoma |
Definition | An endometrial carcinoma that derives_from epithelial cells of glandular origin. |
Source | DiseaseOntology.org |
Alt Ids | DOID:5827 DOID:6650 |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer endometrial cancer endometrial carcinoma endometrial adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA H1047X | Temsirolimus | endometrial adenocarcinoma | predicted - sensitive | detail... |
FGFR2 N549K | PRN1371 | endometrial adenocarcinoma | sensitive | detail... |
PIK3CA Q546X | Copanlisib | endometrial adenocarcinoma | no benefit | detail... |
PIK3CA M1043I | Copanlisib | endometrial adenocarcinoma | no benefit | detail... |
PIK3CA H1047X | Copanlisib | endometrial adenocarcinoma | no benefit | detail... |
PIK3CA E545X | Copanlisib | endometrial adenocarcinoma | no benefit | detail... |
PIK3CA E542K | Copanlisib | endometrial adenocarcinoma | no benefit | detail... |
BRAF L597V | Trametinib | endometrial adenocarcinoma | no benefit | detail... |
BRAF V600E | Dabrafenib + Rabeprazole + Rifampin | endometrial adenocarcinoma | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib + Rabeprazole + Rifampin + Trametinib | endometrial adenocarcinoma | predicted - sensitive | detail... |
FGFR2 K310R FGFR2 N549K | Lirafugratinib | endometrial adenocarcinoma | sensitive | detail... |
FGFR2 K310R FGFR2 N549K | Futibatinib | endometrial adenocarcinoma | sensitive | detail... |
MLH1 negative | Nivolumab | endometrial adenocarcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00492778 | Phase II | Cisplatin | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer | Active, not recruiting | USA | CAN | 0 |
NCT01482728 | Phase I | Dasatinib | Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer | Completed | USA | 0 |
NCT01877564 | Phase II | Metformin | A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women | Completed | USA | 0 |
NCT02065687 | Phase III | Carboplatin + Metformin + Paclitaxel Carboplatin + Paclitaxel | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | Unknown status | USA | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Terminated | USA | FRA | ESP | CAN | 1 |
NCT02208375 | Phase Ib/II | Capivasertib + Olaparib Olaparib + Vistusertib | mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian | Active, not recruiting | USA | 0 |
NCT02335203 | Phase II | Medroxyprogesterone | The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy | Unknown status | USA | 0 |
NCT02611024 | Phase Ib/II | Irinotecan + Lurbinectedin | Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | CHE | 0 |
NCT02697591 | Phase Ib/II | INCAGN01876 | An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
NCT02923349 | Phase Ib/II | INCAGN01949 | A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | GBR | ESP | CHE | 0 |
NCT03018249 | Phase II | Medroxyprogesterone Entinostat + Medroxyprogesterone | Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer | Completed | USA | 0 |
NCT03120624 | Phase I | VSV-hIFNbeta-NIS | VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT03345784 | Phase I | Adavosertib + Cisplatin | WEE1 Inhibitor AZD1775, External Beam Radiation Therapy, and Cisplatin in Treating Patients With Cervical, Vaginal, or Uterine Cancer | Terminated | USA | CAN | 0 |
NCT03348631 | Phase II | Tazemetostat | Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT03586661 | Phase I | Copanlisib + Niraparib | Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Active, not recruiting | USA | 0 |
NCT03660826 | Phase II | Olaparib Cediranib + Olaparib | Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer | Active, not recruiting | USA | CAN | 0 |
NCT03694262 | Phase II | Atezolizumab + Bevacizumab + Rucaparib | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (EndoBARR) | Completed | USA | 0 |
NCT03694834 | Phase I | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab | Window of Opportunity Study of Pembrolizumab in Early Stage, High Grade Obesity-driven Endometrial Cancer | Terminated | USA | 0 |
NCT03832361 | Phase II | Mirvetuximab Soravtansine | Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-alpha Positive Endometrial Cancer | Recruiting | USA | 0 |
NCT03914612 | Phase III | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | Active, not recruiting | USA | CAN | 3 |
NCT04049227 | Phase I | Abemaciclib + Letrozole | Abemaciclib and Letrozole in Treating Patients With Endometrial Cancer | Unknown status | USA | 0 |
NCT04196257 | Phase I | BP1001-A BP1001-A + Paclitaxel | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | Unknown status | USA | 0 |
NCT04291105 | Phase II | Cemiplimab + VSV-hIFNbeta-NIS | Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Recruiting | USA | BRA | 0 |
NCT04393285 | Phase II | Abemaciclib + Letrozole | Abemaciclib and Letrozole to Treat Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT04611139 | Phase I | Pembrolizumab + Seclidemstat | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | Withdrawn | USA | 0 |
NCT04719273 | Phase II | Anastrozole + Onapristone | Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer | Active, not recruiting | USA | 0 |
NCT04750941 | Phase II | Copanlisib | Study of Copanlisib and Ketogenic Diet | Active, not recruiting | USA | 0 |
NCT05255653 | Phase II | Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) | Recruiting | NLD | GBR | FRA | CAN | 0 |
NCT05276973 | Phase I | Carboplatin + Ipatasertib + Paclitaxel | Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer | Recruiting | USA | 0 |
NCT05300048 | Phase I | Serabelisib Nab-paclitaxel + Serabelisib | Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations | Active, not recruiting | USA | 0 |
NCT05325866 | Phase I | Bemarituzumab | A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301) | Recruiting | USA | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 4 |
NCT05332483 | Phase I | Megestrol acetate | Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer (MA-EEC) | Terminated | CAN | 0 |
NCT05538897 | Phase Ib/II | Megestrol acetate Ipatasertib + Megestrol acetate | Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers | Recruiting | USA | 0 |
NCT05548296 | Phase Ib/II | Prexasertib Gemcitabine + Prexasertib | A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma | Recruiting | USA | 0 |
NCT05603910 | Phase I | Lenvatinib + Pembrolizumab | Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma | Recruiting | USA | 0 |
NCT05611931 | Phase III | Selinexor | Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (XPORT-EC-042) | Recruiting | USA | SVK | ITA | ISR | IRL | HUN | GRC | ESP | DEU | CZE | CAN | BEL | AUS | 1 |
NCT05620134 | Phase Ib/II | JK08 | A Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Active, not recruiting | ESP | BEL | 0 |
NCT05705505 | Phase Ib/II | Letrozole + Narazaciclib | Study of Narazaciclib (ON 123300) Plus Letrozole in Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer | Recruiting | USA | 0 |
NCT05712941 | Phase III | G1T38 + Letrozole Letrozole | Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer | Withdrawn | 0 | |
NCT05761951 | Phase II | DKN-01 + Pembrolizumab | Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer | Recruiting | USA | 0 |
NCT05826015 | Phase I | AVB-S6-500 AVB-S6-500 + Paclitaxel | AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer | Withdrawn | 0 | |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05950464 | Phase I | M1774 + ZEN-3694 | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | Recruiting | USA | 0 |
NCT05997017 | Phase II | Nab-rapamycin | Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | Recruiting | USA | 0 |
NCT06003231 | Phase II | Disitamab vedotin | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | Recruiting | USA | ITA | GBR | ESP | CAN | AUS | 1 |
NCT06178614 | Phase I | JNJ-87890387 | A Study of JNJ-87890387 for Advanced Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT06278857 | Phase II | Dostarlimab-gxly | SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr) (SATELLITE) | Recruiting | AUS | 0 |
NCT06366347 | Phase II | Pembrolizumab Abemaciclib + Letrozole | ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab | Recruiting | USA | 0 |
NCT06399757 | Phase Ib/II | APL-5125 | A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06457997 | Phase I | PHN-010 | A Study of PHN-010 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |